This book will be an excellent tool for practitioners seeking an update on the latest developments in the diagnosis and management of cirrhosis and portal hypertension. Among the topics addressed are risk stratification, prognosis, screening and surveillance, impact of etiological and antifibrotic therapy, the gut microbiome and cirrhosis, prevention of decompensation/further decompensation, management of the acute bleeding episode, controversies in pediatrics, and vascular diseases of the liver in cirrhotic and noncirrhotic portal hypertension. The book is a compilation of lectures and…mehr
This book will be an excellent tool for practitioners seeking an update on the latest developments in the diagnosis and management of cirrhosis and portal hypertension. Among the topics addressed are risk stratification, prognosis, screening and surveillance, impact of etiological and antifibrotic therapy, the gut microbiome and cirrhosis, prevention of decompensation/further decompensation, management of the acute bleeding episode, controversies in pediatrics, and vascular diseases of the liver in cirrhotic and noncirrhotic portal hypertension. The book is a compilation of lectures and important consensus statements from the Sixth Baveno International Consensus Workshop on Portal Hypertension, the most recent of a series of workshops held every 5 years for hepatologists with an interest in the field. Portal Hypertension VI will serve as a reference book for clinical and research fellows in Gastroenterology and Hepatology and should inspire new research projects in the areas identified as promising by the experts of the Baveno VI Faculty.
Roberto de Franchis is Head of the Gastroenterology Unit at the L. Sacco University Hospital, Milan, Italy and Professor of Medicine (Gastroenterology) at the University of Milan. He is a member of several specialist societies and an elected Fellow of the American Gastroenterological Association. Dr. de Franchis has published widely in the fields of Gastroenterology and Hepatology in the major medical and hepatology journals. Every five years since 1990 he has organized the International Consensus Workshop on Definitions, Methodology, and Therapeutic Strategies in Portal Hypertension in Baveno, Italy. In 2010 he was organizer and co-chairman of the European School of Hepatology (EASL) in Barcelona, Spain.
Inhaltsangabe
Session 1 - Risk stratification and prognosis.- Session 2 - Screening and surveillance: invasive and noninvasive methods.- Session 3 - Changing scenarios I: Impact of etiological therapy for cirrhosis and of anti-fibrotic therapy on portal hypertension.- Session 4 - The gut microbiome and cirrhosis.- Session 5 - Changing scenarios II: What to do after successful cure of the etiologic factor?.- Session 6 - Management of the acute bleeding episode.- Session 7 - Controversies and challenges in Pediatrics.- Session 8 - Prevention of further decompensation (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy).- Session 9 Vascular diseases of the liver in cirrhotic and non-cirrhotic portal hypertension: coagulation, anti-coagulation, anti-platelet drugs.
Session 1 - Risk stratification and prognosis.- Session 2 - Screening and surveillance: invasive and noninvasive methods.- Session 3 - Changing scenarios I: Impact of etiological therapy for cirrhosis and of anti-fibrotic therapy on portal hypertension.- Session 4 - The gut microbiome and cirrhosis.- Session 5 - Changing scenarios II: What to do after successful cure of the etiologic factor?.- Session 6 - Management of the acute bleeding episode.- Session 7 - Controversies and challenges in Pediatrics.- Session 8 - Prevention of further decompensation (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy).- Session 9 Vascular diseases of the liver in cirrhotic and non-cirrhotic portal hypertension: coagulation, anti-coagulation, anti-platelet drugs.
Session 1 - Risk stratification and prognosis.- Session 2 - Screening and surveillance: invasive and noninvasive methods.- Session 3 - Changing scenarios I: Impact of etiological therapy for cirrhosis and of anti-fibrotic therapy on portal hypertension.- Session 4 - The gut microbiome and cirrhosis.- Session 5 - Changing scenarios II: What to do after successful cure of the etiologic factor?.- Session 6 - Management of the acute bleeding episode.- Session 7 - Controversies and challenges in Pediatrics.- Session 8 - Prevention of further decompensation (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy).- Session 9 Vascular diseases of the liver in cirrhotic and non-cirrhotic portal hypertension: coagulation, anti-coagulation, anti-platelet drugs.
Session 1 - Risk stratification and prognosis.- Session 2 - Screening and surveillance: invasive and noninvasive methods.- Session 3 - Changing scenarios I: Impact of etiological therapy for cirrhosis and of anti-fibrotic therapy on portal hypertension.- Session 4 - The gut microbiome and cirrhosis.- Session 5 - Changing scenarios II: What to do after successful cure of the etiologic factor?.- Session 6 - Management of the acute bleeding episode.- Session 7 - Controversies and challenges in Pediatrics.- Session 8 - Prevention of further decompensation (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy).- Session 9 Vascular diseases of the liver in cirrhotic and non-cirrhotic portal hypertension: coagulation, anti-coagulation, anti-platelet drugs.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
